How many studies have been conducted on Kallidin?

BiohacksAI has indexed 300 PubMed studies on Kallidin, including 6 randomized controlled trials (RCTs). 14% of studies involve human subjects.

What are the main research areas for Kallidin?

The primary research domains for Kallidin are ❤️ Cardiovascular, 🔬 Inflammation, 🦴 Bone & Joint. This is based on analysis of 300 PubMed studies using the BiohacksAI evidence platform.

BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.

Kallidin

A decapeptide bradykinin homolog cleaved from kininogen by kallikreins. It is a smooth-muscle stimulant and hypotensive agent that acts by vasodilatation.

300+ PubMed studies analyzed · 6 RCTs · Evidence Score: 45.8

Research Domains

Kallidin has been studied across 21 research domains including ❤️ Cardiovascular, 🔬 Inflammation, 🦴 Bone & Joint, 💊 Pain, 🔬 Oncology. The primary research focus is ❤️ Cardiovascular with 13% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Kallidin, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Bradykinin

2 shared targets

Loading evidence profile...

This evidence profile for Kallidin is generated deterministically from 300 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.